PURPOSE: Because of the 4 to 6-month interval between a diagnostic amniocentesis and birth, clinical application of amniotic mesenchymal stem cell (AMSC)-based therapies demands a 3-stage cell manufacturing process, including isolation/primary expansion, cryopreservation, and thawing/secondary expansion. We sought to determine the feasibility and cell yield of such a staged cell manufacturing process, within regulatory guidelines. METHODS: Human AMSCs isolated from diagnostic amniocentesis samples (n = 11) were processed under Food and Drug Administration-accredited good manufacturing practice. Expanded cells were characterized by flow cytometry and cryopreserved for 3 to 5 months. Cell release criteria included more than 90% CD29+, CD73+, and CD44+; less than 5% CD34+ and CD45+; negative mycoplasma quantitative polymerase chain reaction (QPCR) and endotoxin assay; and at least 70% viability. RESULTS: Isolation and ample expansion of AMSCs was achieved in 54.5% (6/11) of the samples. Early processing and at least a 2-mL sample were necessary for reliable cell manufacturing. Cell yield before cryopreservation was 223.2 +/- 65.4 x 10(6) cells (44.6-fold expansion), plus a 14.7 x 10(6)-cell backup, after 36.3 +/- 7.8 days. Cell viability postthaw was 88%. Expanded cells maintained a multipotent mesenchymal progenitor profile. CONCLUSIONS: Human amniotic mesenchymal stem cells can be manufactured in large numbers from diagnostic amniocentesis, by an accredited staged processing, under definite procurement guidelines. These data further support the viability of clinical trials of amniotic mesenchymal stem cell-based therapies.
PURPOSE: Because of the 4 to 6-month interval between a diagnostic amniocentesis and birth, clinical application of amniotic mesenchymal stem cell (AMSC)-based therapies demands a 3-stage cell manufacturing process, including isolation/primary expansion, cryopreservation, and thawing/secondary expansion. We sought to determine the feasibility and cell yield of such a staged cell manufacturing process, within regulatory guidelines. METHODS:Human AMSCs isolated from diagnostic amniocentesis samples (n = 11) were processed under Food and Drug Administration-accredited good manufacturing practice. Expanded cells were characterized by flow cytometry and cryopreserved for 3 to 5 months. Cell release criteria included more than 90% CD29+, CD73+, and CD44+; less than 5% CD34+ and CD45+; negative mycoplasma quantitative polymerase chain reaction (QPCR) and endotoxin assay; and at least 70% viability. RESULTS: Isolation and ample expansion of AMSCs was achieved in 54.5% (6/11) of the samples. Early processing and at least a 2-mL sample were necessary for reliable cell manufacturing. Cell yield before cryopreservation was 223.2 +/- 65.4 x 10(6) cells (44.6-fold expansion), plus a 14.7 x 10(6)-cell backup, after 36.3 +/- 7.8 days. Cell viability postthaw was 88%. Expanded cells maintained a multipotent mesenchymal progenitor profile. CONCLUSIONS:Human amniotic mesenchymal stem cells can be manufactured in large numbers from diagnostic amniocentesis, by an accredited staged processing, under definite procurement guidelines. These data further support the viability of clinical trials of amniotic mesenchymal stem cell-based therapies.
Authors: Julie R Fuchs; Amir Kaviani; Jung-Tak Oh; David LaVan; Taturo Udagawa; Russell W Jennings; Jay M Wilson; Dario O Fauza Journal: J Pediatr Surg Date: 2004-06 Impact factor: 2.545
Authors: Pieternella S In 't Anker; Sicco A Scherjon; Carin Kleijburg-van der Keur; Godelieve M J S de Groot-Swings; Frans H J Claas; Willem E Fibbe; Humphrey H H Kanhai Journal: Stem Cells Date: 2004 Impact factor: 6.277
Authors: Amir Kaviani; Kristine Guleserian; Tjörvi E Perry; Russell W Jennings; Moritz M Ziegler; Dario O Fauza Journal: J Am Coll Surg Date: 2003-04 Impact factor: 6.113
Authors: Sveva Bollini; Michela Pozzobon; Muriel Nobles; Johannes Riegler; Xuebin Dong; Martina Piccoli; Angela Chiavegato; Anthony N Price; Marco Ghionzoli; King K Cheung; Anna Cabrelle; Paul R O'Mahoney; Emanuele Cozzi; Saverio Sartore; Andrew Tinker; Mark F Lythgoe; Paolo De Coppi Journal: Stem Cell Rev Rep Date: 2011-06 Impact factor: 5.739
Authors: Jennifer Petsche Connell; Gulden Camci-Unal; Ali Khademhosseini; Jeffrey G Jacot Journal: Tissue Eng Part B Rev Date: 2013-03-14 Impact factor: 6.389